Polewaczyk James F's Form 4 filing
IDEXX Laboratories Inc (IDXX) · filed Mar 7, 2024
- Accession no.
- 0000874716-24-000065
- Filed
- Mar 7, 2024
- Trade date
- Mar 6, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $4.53M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Polewaczyk James FCIK 0001389046 | Officer (Executive Vice President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2024 | Common Stock | MOption exerciseAcquired | +755 | $206.94 | +$156,239.7 | 11,466.23 | Direct | |
| Mar 6, 2024 | Common Stock | MOption exerciseAcquired | +483 | $206.94 | +$99,952.02 | 11,949.23 | Direct | |
| Mar 6, 2024 | Common Stock | MOption exerciseAcquired | +2,226 | $288.78 | +$642,824.28 | 14,175.23 | Direct | |
| Mar 6, 2024 | Common Stock | MOption exerciseAcquired | +4,640 | $544.08 | +$2,524,531.2 | 18,815.23 | Direct | |
| Mar 6, 2024 | Common Stock | SSaleDisposed | −4,134 | $557.94F1 | −$2,306,523.96 | 14,681.23 | Direct | |
| Mar 6, 2024 | Common Stock | SSaleDisposed | −3,290 | $558.88F2 | −$1,838,715.2 | 11,391.23 | Direct | |
| Mar 6, 2024 | Common Stock | SSaleDisposed | −680 | $559.33F3 | −$380,344.4 | 10,711.23 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2024 | Common Stock | MOption exerciseDisposed | −755 | $0.00 | $0 | 0 | Direct | |
| Mar 6, 2024 | Common Stock | MOption exerciseDisposed | −483 | $0.00 | $0 | 0 | Direct | |
| Mar 6, 2024 | Common Stock | MOption exerciseDisposed | −2,226 | $0.00 | $0 | 0 | Direct | |
| Mar 6, 2024 | Common Stock | MOption exerciseDisposed | −4,640 | $0.00 | $0 | 1,363 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average price of the shares sold ranging from a low of $557.33 to a high of $558.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
Represents the weighted average price of the shares sold ranging from a low of $558.45 to a high of $559.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average price of the shares sold ranging from a low of $559.51 to a high of $559.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.